Business Context and Reporting Period
This Form 6-K filing by NewGenIvf Group Ltd covers the month of November 2025. The report serves as a notification of a corporate action regarding the company's capital structure rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on a reverse stock split announcement.
Material Changes
The primary material change is a one-for-five reverse stock split of the company's issued and unissued shares. Key details include:
- Effective Date: December 1, 2025, at 12:01 a.m. (ET).
- Share Reduction: Outstanding Class A Ordinary Shares will decrease from 6,585,672 to approximately 1,317,135.
- Trading Symbol: Shares will continue to trade under "NIVF" on the Nasdaq Capital Market.
- CUSIP Update: The new CUSIP number is G0544E402.
- Fractional Shares: No fractional shares will be issued; shareholders entitled to fractions will receive one full post-split share.
- Adjustments: All outstanding options, warrants, and convertible securities will be adjusted by dividing the exercisable share count by five.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies beyond the mechanics of the reverse stock split.
Investor Verification Checklist
- Confirm the new CUSIP number (G0544E402) in brokerage accounts prior to December 1, 2025.
- Verify the adjusted number of shares held post-split (1/5th of pre-split holdings, rounded up for fractional entitlements).
- Review the impact of the split on the exercise price and share count of any held options or warrants.
- Monitor the stock price on the Nasdaq Capital Market starting December 1, 2025, for split-adjusted trading.